

## **TITLE PAGE**

### **Title**

Ketamine-assisted psychotherapy provides lasting and effective results in the treatment of depression, anxiety and post traumatic stress disorder at 3 and 6 months: Findings from a large single-arm retrospective effectiveness trial

### **Authors**

Ryan Yermus MD, Michael Verbora MBA, MD, Sidney Kennedy MD, Robert McMaster MD, Sarah Kratina BScN, RN, Elizabeth Wolfson PhD, Ben Medrano MD, Nathan Bryson PhD, Nabid Zaer MD, John Bottos, Varun Setlur, Chris Lo PhD

### **Author Affiliations**

Field Trip Health, Toronto, Ontario (Yermus, Verbora, Wolfson, Zaer, Bottos, Setlur); Family Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario (Verbora); Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario (Kennedy, McMaster, Lo); Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario (Kratina); Social and Behavioural Health Sciences Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario (Lo); Psychology, School of Social and Health Sciences, James Cook University, Singapore (Lo); Field Trip Health NY & DC, New York, NY & Washington, District of Columbia, (Medrano); Nue Life Medical Group, Delaware (Medrano); Reunion Neuroscience, Toronto, Ontario (Bryson), School of Biological Sciences and Applied Chemistry, Seneca College, Toronto, Ontario (Zaer).

### **Corresponding Author**

Chris Lo PhD, School of Social and Health Sciences, James Cook University, 149 Sims Dr. Singapore 387380.

Email: [chris.lo@utoronto.ca](mailto:chris.lo@utoronto.ca).

### **Manuscript Word Count**

2,881

## Key Points

**Question** What are the lasting effects of Ketamine-Assisted Psychotherapy on psychological distress?

**Findings** In this retrospective single-arm effectiveness trial that included 1806 adults, there were large effect sizes at 3 months on depression, anxiety, and post traumatic stress ( $d$ 's=0.75-0.86) that were sustained at 6 months.

**Meaning** These findings suggest that Ketamine-Assisted Psychotherapy is an effective treatment option with substantial clinical benefits detected up to half a year.

## Abstract

**IMPORTANCE** Ketamine-Assisted Psychotherapy (KAP) is an emerging treatment option to alleviate treatment resistant affective disorders, but its long term effectiveness remains unclear.

**OBJECTIVE** To examine the treatment effects of KAP on anxiety, depression, and post traumatic stress disorder (PTSD) at 1, 3, and 6 months post treatment.

**DESIGN, SETTING, AND PARTICIPANTS** This retrospective single-arm effectiveness trial included self-reported outcomes from 1806 adults with a history of depression, anxiety, or PTSD who had not responded to prior treatment interventions and received KAP administered across 11 Field Trip Health clinics in North America between March 13, 2020 and June 16, 2022.

**INTERVENTION** KAP consisting of 4-6 guided ketamine sessions (administered via intramuscular injection or sublingual lozenge) with psychotherapy-only visits after doses 1 and 2 and then after every 2 subsequent doses. Mean number of doses administered was 4, SD=3, and mean number of psychotherapy sessions was 3, SD=2.

**MAIN OUTCOMES AND MEASURES** Primary outcomes were changes in depression, anxiety, and PTSD at 3 months relative to baseline, assessed respectively using the 9-item Patient Health Questionnaire (PHQ-9), the 7-item Generalized Anxiety Disorder measure (GAD-7), and the 6-item PTSD Checklist (PCL-6). Secondary outcomes were changes at 1 and 6 months relative to baseline.

**RESULTS** Large treatment effects were detected at 3 months ( $d$ 's=0.75-0.86) that were sustained at 6 months ( $d$ 's=0.61-0.73). Case reductions (identified based on cut-off values) ranged from 39-41% at 3 months and 29-37% at 6 months. 50-75% reported a minimal clinically important difference at 3 months and 48-70% at 6 months.

**CONCLUSIONS AND RELEVANCE** KAP produced sustained reductions in anxiety, depression, and PTSD, with symptom improvement lasting well beyond the duration of dosing sessions. These effects extended to as much as 5 months after the last KAP session. Given the growing mental health care crises and the need for effective therapies and models of care, especially for intractable psychiatric mood related disorders, these data would support the consideration of KAP as a viable alternative. Further prospective clinical research should be undertaken to provide further evidence on the safety and effectiveness of ketamine within a psychotherapeutic context.

**TRIAL REGISTRATION** Clinicaltrials.gov Identifier NCT05604794

*Keywords:* Anxiety, Depression, Ketamine, Psychedelic, Psychotherapy, Post Traumatic Stress Disorder

*Word Count:* 2,881

## Introduction

Over the past two decades, ketamine has demonstrated the potential to produce rapid and sustained antidepressant effects and therapeutic outcomes for several psychiatric conditions.<sup>1</sup> Most studies to date have looked at the administration of ketamine via intravenous (IV) administration<sup>2</sup> however, ketamine's application has evolved to include psychotherapeutic practices to reduce its unwanted dissociative effects while bolstering positive antidepressant, anxiolytic, anti-stress, and other positive mood effects.<sup>3</sup> Ketamine-Assisted Psychotherapy (KAP) has borrowed from earlier research on psychedelic substances such as lysergic acid diethylamide (LSD) to facilitate deep and rapid introspective work within an organized psychotherapeutic framework.<sup>4</sup>

Currently, ketamine is the only legal psychedelic medicine to treat persistent and severe psychological distress in North America, making it well-suited for widespread psychotherapeutic implementation. Preliminary clinical trial data are increasingly supportive of the safety and efficacy of KAP to alleviate anxiety, depression, and post traumatic stress disorder (PTSD),<sup>5,6</sup> with more trials underway worldwide. In a recent study of patients with moderate to severe depression or anxiety, ketamine-assisted therapy was found to have immediate effects on depression and anxiety; outcomes showed persistent efficacy to 2 and 4 weeks in most treated subjects.<sup>7</sup> However, the impact on post-treatment quality of life is understudied, and there remains a need to clarify the long term effectiveness of KAP for a variety of mood related disorders.

In this study, we conducted a retrospective analysis of outcomes from patients who were treated with KAP at Field Trip Health centres across North America and agreed to participate in an open label evaluation of outcomes up to 6 months after the intervention. Ketamine was administered via intramuscular injection or sublingual lozenge. Primary outcomes were changes in depression, anxiety, and post traumatic stress at 3 months from baseline. Secondary outcomes were changes at 1 and 6 months from baseline.

## Methods

### Ethics and Design

Ethics approval for this study was granted by Veritas Independent Review Board (#2022-3067-11240-5). The study was a retrospective single-arm effectiveness trial of KAP involving chart review of patient self-reported mental health outcomes assessed at baseline, 1, 3, and 6 months.

### Participants and Procedure

Data was collected from clients treated across 11 Field Trip Health clinics in North America: 1) Toronto, ON, Canada; 2) Vancouver, BC, Canada; 3) Fredericton, NB, Canada; 4) New York City, NY, USA; 5) Atlanta, GA, USA; 6) Chicago, IL, USA; 7) Houston, TX, USA; 8) Seattle, WA, USA; 9) Santa Monica, CA, USA; 10) San Diego, CA, USA; 11) Washington, DC, USA; between March 13, 2020, and June 16, 2022. Participants included in the analysis had a documented history of depression or anxiety that showed lack of adequate response to previous treatment(s) or presented with PTSD as assessed by the Structured Clinical Interview for DSM 5 (SCID 5).<sup>8</sup> Patient assessments were performed using a proprietary digital platform (PortalTM) through the Electronic Medical Records (EMR) system at 1, 3, and 6 months. The completion of measures was voluntary after the collection of signed written informed consent.

### Treatment

Prospective clients were either self-referred in the United States or referred for treatment by a health care provider to one of the 3 Canadian clinic locations. All clients were assessed by a psychiatrist or psychiatric nurse practitioner to determine the appropriateness for treatment. Inclusion criteria included signed written informed consent; being over the age of 18; and having a documented, prior diagnosis by a psychiatrist of one or more of Major Depressive Disorder (MDD), Bipolar Depression, Generalized Anxiety Disorder, Obsessive Compulsive Disorder (OCD), Eating Disorder, or a significant history of trauma and/or a formal diagnosis of PTSD as per the DSM 5.

Exclusion criteria included pregnant women and nursing mothers, although Postpartum Depression (PPD) was considered on a case-by-case basis in consultation with the National Medical Director; a relative (not absolute) contraindication for individuals with a Body Mass Index (BMI) above 35; any individual who has met DSM 5 criteria for a Substance Use Disorder in the past 3 months and had been unable to exhibit a reduction in use; Psychosis or psychotic symptoms; Active Mania: Bipolar 1 (chronic non-disruptive hypomania is an exception at the discretion of the treatment team); Borderline Personality Disorder; uncontrolled medical disorders or physical conditions with negative interaction with ketamine; individuals with symptomatic acute brain injury within 90 days of serious injury; individuals diagnosed with moderate to severe sleep apnea; and individuals who were unable to identify a person or service to assure their safe transport to home post treatment.

Upon medical approval, clients met with a licensed therapist to discuss preparation for KAP and to initiate a therapeutic relationship. Dosing with ketamine was completed via intramuscular injection in the United States and Vancouver and via sublingual lozenge in Toronto and Fredericton. Clients were offered personalized treatment recommendations consisting of 4-6 guided ketamine sessions with psychotherapy-only integration visits after doses 1 and 2 and then after every 2 subsequent doses.

Initial dosing via intramuscular injection was of 25-35mg with the option to titrate to 50-70mg at visit 2 and up to 100mg for subsequent visits. The initial dose for lozenges was 200mg with the option to increase by 50-100mg per visit up to 500mg. Ketamine doses were not scheduled on consecutive days and could be interspersed by 1 week or more. Some participants completed additional sessions beyond dose 6. Integration sessions were based on motivational interviewing and behavioural activation, but therapists had the option to incorporate other modalities depending on their assessment of the client's needs and goals.

Ketamine dosing was completed in Field Trip Health clinics using an approach consistent with psychedelic studies in a setting designed to be aesthetically and functionally conducive with a state of relaxation. Clients were dosed while seated in a comfortable reclining chair, wearing an eye shade and listening to curated music playlists. Therapists were present to support clients during dosing sessions while medical staff monitored heart rate, blood pressure, respiration rate and oxygen saturation throughout the session.

## **Outcome Measures**

Symptoms of depression were assessed by the 9-item Patient Health Questionnaire (PHQ-9).<sup>9</sup> PHQ scores may range from 0-27 with higher scores indicating more severe depressive symptoms. A PHQ cut-off score of 15 has been validated to identify cases with at least moderately-severe depression.<sup>9</sup> A change of 3 points has been considered a minimal clinically important difference (MCID).<sup>10,11</sup>

Symptoms of anxiety were assessed by the 7-item Generalized Anxiety Disorder measure (GAD-7).<sup>12</sup> GAD scores may range from 0-21 with higher scores indicating more severe anxiety symptoms. A GAD cut-off score of 10 has been validated to identify cases with at least moderate anxiety.<sup>12</sup> A change of 3 points has been considered an MCID.<sup>10,11</sup>

Symptoms of post traumatic stress were assessed using the 6-item PTSD Checklist (PCL-6).<sup>13</sup> PCL scores may range from 6-30, with higher scores indicating more severe stress symptoms. A PCL cut-off score of 14 has been validated to identify cases of PTSD.<sup>13</sup> A change of 5 points may be considered an MCID.<sup>14</sup>

## **Statistical Analysis**

We report descriptive statistics for the sample and analyze the extent of loss to follow-up. The primary analysis was by Intention to Treat (ITT). We used linear mixed modelling to fit growth curves describing the normative patient trajectory on each outcome.<sup>15</sup> The main analysis involved fitting linear and curvilinear trends over time and estimating mean differences at each endpoint compared to the baseline. Cohen's d was reported as a standardized measure of effect size for mean differences (d=0.2 is a small effect, 0.5 medium, and 0.8 large).

We reported secondary analyses on the effect of doses administered, controlling for age, gender, and site differences; case reductions in depression, anxiety, and PTSD based on cut-offs; and proportions of treatment responders based on MCIDs. As a sensitivity analysis, we used the Expectation-Maximization (EM) and Markov Chain Monte Carlo (MCMC) algorithms to multiply impute missing follow-up data.<sup>16</sup> We simulated 1000 datasets per outcome measure, calculated the effects per imputation, and combined the findings across imputations to achieve the best estimates for comparison to the initial estimates.

## Results

### Descriptive Statistics

In total 1806 participants entered treatment (see Table 1 for sample characteristics). The mean age was 42 years,  $SD=12$ , and 52% of participants were female. Most individuals had a primary diagnosis of depression (24%), anxiety (28%), or PTSD (25%). The mean number of assessments completed per participant was 2.26,  $SD=2.01$ . 18% of baseline participants provided a 3-month assessment, and 5% provided a 6-month assessment (see Figure 1 for patient flow diagram).

The mean number of doses was 4,  $SD=3$ , with 12% (210/1806) receiving more than 6 doses and 24% (440/1806) receiving 1 dose. Ketamine was administered sublingually to 32% (579/1806) of the sample and intramuscularly to 68% (1227/1806). The mean number of (psychotherapeutic) integration sessions was 3,  $SD=2$ , with 20% (365/1806) receiving more than 4 sessions.

### Lost to Follow-up Analyses

Lost to follow-up refers to individuals who did not provide a follow-up assessment and is separate from treatment status. Lost to follow-up was associated with less pretreatment psychological distress. Compared to those who provided a 3-month assessment, those who did not had lower baseline scores on PHQ,  $M_{Diff}=-1.83$ ,  $CI_{.95}(-1.09, -2.58)$ ,  $p<.0001$ ,  $d=0.28$ , and PCL,  $M_{Diff}=-1.56$ ,  $CI_{.95}(-0.86, -2.25)$ ,  $p<.0001$ ,  $d=0.28$ . Compared to those who provided a 6-month assessment, those who did not had lower baseline scores on GAD,  $M_{Diff}=-1.58$ ,  $CI_{.95}(-0.26, -2.90)$ ,  $p=0.02$ ,  $d=0.28$ , and PCL,  $M_{Diff}=-1.86$ ,  $CI_{.95}(-0.51, -3.22)$ ,  $p=0.007$ ,  $d=0.33$ . Overall, the frequency of missing assessments had a tendency to be negatively correlated with baseline scores on the PHQ,  $r=-0.13$ ,  $p<.0001$ ; the GAD,  $r=-0.06$ ,  $p=0.02$ ; and the PCL,  $r=-0.10$ ,  $p<.0001$ .

### Primary and Secondary Outcomes

The primary outcomes were changes at 3 months from baseline, and secondary outcomes were changes at 1 and 6 months from baseline. There was a significant reduction on the PHQ at 1 month,  $d=0.50$ , which was amplified at 3 months,  $d=0.85$ , and remained detectable at 6 months,  $d=0.73$ . There was a reduction on the GAD at 1 month,  $d=0.47$ , which was amplified at 3 months,  $d=0.86$ , and remained detectable at 6 months,  $d=0.73$ . There was a reduction on the PCL at 1 month,  $d=0.38$ , which was amplified at 3 months,  $d=0.75$ , and remained detectable at 6 months,  $d=0.61$ . See Table 2 for details.

### Dose and Other Predictive Factors

We entered dose as a predictive factor, controlling for age, gender, and site. Dose referred to the number of doses administered at the time of assessment and was a within-subjects, time-varying factor. There was a significant effect of dose on PHQ,  $b=-1.20$ ,  $se=0.061$ ,  $p<.0001$ , on GAD,  $b=-0.97$ ,  $se=0.055$ ,  $p<.0001$ , and on PCL,  $b=-0.92$ ,  $se=0.055$ ,  $p<.0001$ . These coefficients indicate that per administered dose, there was a reduction of 1.20 points on the PHQ and approximately 1 point reductions on the GAD and PCL.

There were main effects of site, age, and gender. There were medium to large site differences due to the requirement for clinician treatment referral in Canada. Overall, Canadian sites treated cases with more intense symptomatology than American sites (which permitted self-referral):  $d=0.80$ ,  $M_{Diff}=5.19$ ,  $CI_{.95}(4.19, 6.20)$  on PHQ;  $d=0.43$ ,  $M_{Diff}=2.43$ ,  $CI_{.95}(1.58, 3.28)$  on GAD;  $d=0.58$ ,  $M_{Diff}=3.27$ ,  $CI_{.95}(2.41, 4.14)$  on PCL; all  $p$ 's  $<.0001$ . There were some small age effects. Compared to younger clients (estimated at 30 years or mean age - 1SD), older clients (estimated at 54 years or mean age + 1SD) had lower



overall PHQ scores,  $d=0.23$ ,  $M_{Diff}=-1.53$ ,  $CI_{.95}(-2.09, -0.98)$ ,  $p<.0001$ , lower overall GAD scores,  $d=0.31$ ,  $M_{Diff}=-1.73$ ,  $CI_{.95}(-2.20, -1.25)$ ,  $p<.0001$ , and lower overall PCL scores,  $d=0.14$ ,  $M_{Diff}=-0.78$ ,  $CI_{.95}(-1.27, -0.30)$ ,  $p=0.002$ . There was one marginally significant gender difference. Compared to men, women had a slight tendency to report higher overall PHQ scores,  $d=0.08$ ,  $M_{Diff}=0.54$ ,  $CI_{.95}(-0.005, 1.08)$ ,  $p=0.05$ .

### Caseness

There were statistically significant reductions in the proportions of depressed, anxious, and PTSD cases as identified by scoring above or equal to clinical cut-off values on each outcome measure (see Table 3). Case reductions showed similar patterns of change across outcomes as in the growth curve models, with the largest case reductions at the primary 3-month endpoint.

In the 315 patients who provided a 3-month PHQ assessment, the depression case rate dropped from 56% at baseline to 17% at 3 months. In the 305 patients who provided a 3-month GAD assessment, the anxiety case rate dropped from 67% at baseline to 26% at 3 months. In the 299 patients who provided a 3-month PCL assessment, the PTSD case rate dropped from 84% at baseline to 45% at 3 months.

In the 92 patients who provided a 6-month PHQ assessment, the depression case rate dropped from 51% at baseline to 16% at 6 months. In the 72 patients who provided a 6-month GAD assessment, the anxiety case rate dropped from 69% at baseline to 32% at 6 months. In the 69 patients who provided a 6-month PCL assessment, the PTSD case rate dropped from 87% at baseline to 58% at 6 months.

### Treatment Responders

See Table 4. In the 315 patients who provided a 3-month PHQ assessment, 75% reported a 3-point MCID compared to baseline. In the 305 patients who provided a 3-month GAD assessment, 68% reported a 3-point MCID compared to baseline. In the 299 patients who provided a 3-month PCL assessment, 50% reported a 5-point MCID compared to baseline.

In the 92 patients who provided a 6-month PHQ assessment, 70% reported a 3-point MCID compared to baseline. In the 72 patients who provided a 6-month GAD assessment, 65% reported a 3-point MCID compared to baseline. In the 69 patients who provided a 6-month PCL assessment, 48% reported a 5-point MCID compared to baseline.

### Simulations

We multiply imputed 1000 datasets per outcome measure in which missing values were filled in with simulated values, achieving relative efficiencies of 0.999. This method allows us to evaluate what would have happened if individuals who were lost to follow-up were retained in the data analysis and is meant to mitigate the poor retention rate. For each imputation, we specified linear mixed models to directly estimate mean differences at each endpoint from baseline. These parameters were combined across imputations to achieve best estimates of mean differences (see Table 2). There were no apparent differences between imputed estimates and those based on the analysis of available cases only. Many imputed estimates indicated a slightly larger effect than initially detected.

### Discussion

This single-arm effectiveness trial examined the largest dataset to date of long term outcomes in clients who received Ketamine-Assisted Psychotherapy. KAP aimed to alleviate symptoms of depression, anxiety, and post traumatic stress. We found evidence of large to moderately large treatment effects at 3 and 6 months,  $d$ 's ranging from 0.61-0.86 and corresponding to 5-6 point reductions on the PHQ, 4-5 point reductions on GAD, and 3-4 point reductions on PCL. There was a consistent pattern of change across measures characterized by reductions in psychological distress that were most apparent at 3 months. There were approximately 40% reductions in caseness for depression, anxiety, and PTSD at this primary endpoint, and treatment responders ranged from 50-75%. This clinical benefit was sustained at 6 months.

Gender and age differences in outcomes were small to minimal, indicating the broad suitability of KAP. Over 90% of individuals entered treatment within 3 months of intake, and 76% completed more than

1 ketamine dose. Each ketamine dose was associated with 1-point reductions on the PHQ, GAD, and PCL, in support of the current program, which recommends 4-6 ketamine sessions. This can be anticipated to produce an estimated 4-6 point reduction across outcome measures over time, larger than the MCID thresholds of 3-5 points for indicating treatment response. However, we caution that the effects of dose must be interpreted within the context of KAP, which involved integration sessions that occurred in lock step with ketamine dosing to activate and reinforce the psychological gains from this experience. Occasional side effects included nausea, vomiting, and increases in blood pressure, not requiring medical intervention nor requiring patients to be taken to a hospital. Findings may be most generalizable to populations with treatment-resistant depression, anxiety, or PTSD eligible for KAP treatment according to Fieldtrip Health guidelines. Given the lack of novel treatment options in the behavioral health space, KAP represents a viable alternative that should be more widely considered.

## **Limitations**

The main limitation of this study is the substantial attrition during the 6 month follow-up period. The importance of completing the follow-up assessments was not made clear to patients and increased efforts are needed to improve survey completion rates moving forward. The treatment effects demonstrated here are based on those who provided follow-up data. These individuals tended to have more pretreatment distress and may be considered a clinical priority. The estimates of treatment effect at 6 months are less reliable than at 3 months. To the extent possible, we examined these issues using multiple imputation of missing data. The estimates of treatment effect from these simulation analyses were stable and consistent with the analysis of only available cases.

Although promising, a future prospective clinical trial with improved data collection is needed. Other limitations include the retrospective nature of the study and lack of a randomised control group. Further study is also needed to clarify the indications and contraindications of KAP for patient subpopulations and the tailoring of treatment to further improve upon individual outcomes.

## **Conclusion**

This large retrospective single-arm trial found that Ketamine-Assisted Psychotherapy is an effective treatment achieving sustained and clinically meaningful reductions in depression, anxiety, and post traumatic stress for up to half a year.



## ARTICLE INFORMATION

**Corresponding Author:** Chris Lo PhD, School of Social and Health Sciences, James Cook University, 149 Sims Dr. Singapore 387380. Email: [chris.lo@utoronto.ca](mailto:chris.lo@utoronto.ca).

**Author Affiliations:** Field Trip Health, Toronto, Ontario (Yermus, Verbora, Wolfson, Zaer, Bottos, Setlur); Family Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario (Verbora); Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario (Kennedy, McMaster, Lo); Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario (Kratina, Lo); Social and Behavioural Health Sciences Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario (Lo); Psychology, School of Social and Health Sciences, James Cook University, Singapore (Lo); Field Trip Health NY & DC, New York, NY & Washington, District of Columbia, (Medrano); Nue Life Medical Group, Delaware (Medrano); Reunion Neuroscience, Toronto, Ontario (Bryson), School of Biological Sciences and Applied Chemistry, Seneca College, Toronto, Ontario (Zaer).

**Author Contributions:** Drs Yermus and Lo had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

*Concept and design:* Yermus, Verbora, Lo.

*Acquisition, analysis, or interpretation of data:* All authors.

*Drafting of the manuscript:* All authors.

*Critical revision of the manuscript for important intellectual content:* All authors.

*Statistical analysis:* Setlur, Bottos, Yermus, Lo.

*Obtained funding:* Yermus, Lo.

*Administrative, technical, or material support:* Setlur, Zaer, Bottos.

*Supervision:* Yermus, Lo.

**Conflict of Interest Disclosures:** Dr Yermus is a co-founder of Field Trip Health and formerly served as Chief Clinical Officer. He received a salary and stock options for his work in this regard. Dr Verbora, is the Medical Director of Field Trip Health & Wellness, and he receives a salary and stock options for his work in this regard. Dr Kennedy has received funding for Consulting or Speaking engagements from Abbvie, Boehringer-Ingelheim, Janssen, Lundbeck, Lundbeck Institute, Merck, Otsuka Pfizer, Sunovion and Servier. He has received Research Support from Abbott, Brain Canada, CIHR (Canadian Institutes of Health Research), Janssen, Lundbeck, Neurocrine, Ontario Brain Institute, Otsuka, Pfizer, SPOR (Canada's Strategy for Patient-Oriented Research). He has stock/stock options in Field Trip Health. Dr McMaster was an advisor to Field Trip Health, and owns shares in Field Trip Health and Wellness and Reunion Neuroscience. Ms Kratina has no disclosures to report. Dr Wolfson is the Vice President of Clinical Services at Field Trip Health and Wellness. She receives a salary and stock options for her work in this regard. Dr Medrano was the Medical Director of Field Trip Health. He is the current Medical Director of Nue.Life Medical Group that provides medical and therapy services for Field Trip At Home. He receives salary and stock options for all of these from both Field Trip and Nue.Life. Dr Bryson was Chief Scientific Officer of Field Trip Discovery, formerly a division of Field Trip Health, but now known as Reunion Neuroscience, and he continues to own shares in Field Trip Health and Wellness, and further, as Chief Scientific Officer of Reunion Neuroscience has an on-going mutual service agreement with Field Trip Health and Wellness. Mr Zaer is a clinical consultant at Field Trip Health and receives a salary for his work. Mr Bottos is the Manager of Health Platforms at Field Trip Health. He receives a salary and stock options for his work in this regard. Mr Setlur was the Director of Data at Field Trip Health. He received a salary and stock options for his work in this regard. Dr Lo received an initial consultation fee from Field Trip Health.

**Funding/Support:** This publication of this study was supported by the Field Trip Health & Wellness Research Grant.

**Role of Funder/Sponsor:** Employees of the funder of this research were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Data Sharing Statement:** There is no plan to share data, although requests may be made for access.

**Trial Protocol:** Trial protocol will be available at [clinicaltrials.gov](https://clinicaltrials.gov) after the results are published.

## References

1. Walsh Z, Mollaahmetoglu OM, Rootman J, et al. Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. *BJPsych open*. 2022;8(1)
2. Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. *JAMA psychiatry*. 2017;74(4):399-405.
3. Greenway KT, Gareil N, Jerome L, Feduccia AA. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. *Expert Review of Clinical Pharmacology*. 2020;13(6):655-670.
4. Pahnke WN, Kurland AA, Unger S, Savage C, Grof S. The experimental use of psychedelic (LSD) psychotherapy. *Jama*. 1970;212(11):1856-1863.
5. Dore J, Turnipseed B, Dwyer S, et al. Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. *Journal of psychoactive drugs*. 2019;51(2):189-198.
6. Duek O, Kelmendi B, Pietrzak RH, Harpaz-Rotem I. Augmenting the treatment of PTSD with ketamine—a review. *Current Treatment Options in Psychiatry*. 2019;6(2):143-153.
7. Hull TD, Malgaroli M, Gazzaley A, et al. At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. *Journal of Affective Disorders*. 2022;314:59-67.
8. Osório FL, Loureiro SR, Hallak JEC, et al. Clinical validity and intrarater and test–retest reliability of the Structured Clinical Interview for DSM\_5–Clinician Version (SCID\_5\_CV). *Psychiatry and clinical neurosciences*. 2019;73(12):754-760.
9. Kroenke K, Spitzer RL, Williams JB. The PHQ\_9: validity of a brief depression severity measure. *Journal of general internal medicine*. 2001;16(9):606-613.
10. Kroenke K, Wu J, Yu Z, et al. The patient health questionnaire anxiety and depression scale (PHQ-ADS): Initial validation in three clinical trials. *Psychosomatic medicine*. 2016;78(6):716.
11. Kounali D, Button KS, Lewis G, et al. How much change is enough? Evidence from a longitudinal study on depression in UK primary care. *Psychological Medicine*. 2020:1-8.
12. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Archives of internal medicine*. 2006;166(10):1092-1097.
13. Lang AJ, Stein MB. An abbreviated PTSD checklist for use as a screening instrument in primary care. *Behaviour research and therapy*. 2005;43(5):585-594.
14. Lang AJ, Wilkins K, Roy-Byrne PP, et al. Abbreviated PTSD Checklist (PCL) as a guide to clinical response. *General hospital psychiatry*. 2012;34(4):332-338.
15. Leyland AH, Groenewegen PP. *Multilevel modelling for public health and health services research: health in context*. Springer Nature; 2020.
16. Dong Y, Peng C-YJ. Principled missing data methods for researchers. *SpringerPlus*. 2013;2(1):1-17.

**Table 1. Sample Characteristics**

<b>Baseline and Time-Invariant Variables</b>	<b>N</b>	<b>Mean</b>	<b>SD</b>
Age	1806	42.12	11.60
Frequency of Ketamine Doses Administered	1806	4.04	2.70
Frequency of Integration Sessions Delivered	1711	3.21	2.03
	<b>N</b>	<b>Frequency</b>	<b>Percent</b>
<b>Gender</b>			
Female	1806	948	52.49
Male	1806	850	47.07
Non-Binary	1806	8	0.44
<b>Primary Diagnosis</b>			
Anxiety	1745	488	27.97
Bipolar Disorder	1745	16	0.92
Depression	1745	418	23.95
Eating Disorder	1745	27	1.55
Obsessive-Compulsive Disorder	1745	47	2.69
PTSD	1745	442	25.33
Substance Abuse	1745	85	4.87
Other	1745	222	12.72
<b>Caseness at Baseline</b>			
T0 PHQ $\geq$ 15	1805	821	45.48
T0 GAD $\geq$ 10	1802	1137	63.10
T0 PCL $\geq$ 14	1797	1364	75.90
<b>Time-Dependent Variables</b>	<b>N</b>	<b>Mean</b>	<b>SD</b>
T0 PHQ	1805	13.60	6.51
T1 PHQ	331	10.26	6.78
T3 PHQ	316	8.29	6.02
T6 PHQ	92	8.92	6.06
T0 GAD	1802	11.86	5.60
T1 GAD	334	8.79	5.84
T3 GAD	306	6.73	5.03
T6 GAD	72	8.39	5.84
T0 PCL	1797	17.98	5.63
T1 PCL	328	15.30	5.49
T3 PCL	300	13.88	4.98
T6 PCL	69	15.22	5.48

T0 = baseline; T1 = 1-month assessment; T3 = 3-month assessment; T6 = 6-month assessment.

**Table 2. Predicted Mean Differences from Linear Mixed Model Analyses of Available Cases and Multiple Imputation**

Outcome	M1 Time point	M2 Time point	M1	M2	diff <sub>M1-M2</sub>	Lower CL <sub>-.95</sub>	Upper CL <sub>.95</sub>	d	Imputed diff <sub>M1-M2</sub>	Imputed Lower CL <sub>-.95</sub>	Imputed Upper CL <sub>.95</sub>	Imputed d
PHQ	T1	T0	10.38	13.62	-3.23***	-3.57	-2.90	0.50	-3.88***	-4.49	-3.28	0.60
	T3	T0	8.06	13.62	-5.56***	-5.96	-5.15	0.85	-5.96***	-6.57	-5.34	0.92
	T6	T0	8.88	13.62	-4.74***	-5.68	-3.80	0.73	-4.79***	-5.83	-3.75	0.74
GAD	T1	T0	9.24	11.89	-2.65***	-2.95	-2.34	0.47	-3.16***	-3.71	-2.61	0.56
	T3	T0	7.09	11.89	-4.80***	-5.17	-4.44	0.86	-5.27***	-5.80	-4.74	0.94
	T6	T0	7.78	11.89	-4.10***	-5.02	-3.18	0.73	-4.04***	-5.24	-2.84	0.72
PCL	T1	T0	15.85	17.99	-2.14***	-2.44	-1.83	0.38	-2.72***	-3.26	-2.18	0.48
	T3	T0	13.75	17.99	-4.24***	-4.60	-3.87	0.75	-4.53***	-5.08	-3.98	0.80
	T6	T0	14.55	17.99	-3.44***	-4.38	-2.50	0.61	-3.57***	-4.71	-2.42	0.63

T0 = baseline; T1 = 1-month assessment; T3 = 3-month assessment; T6 = 6-month assessment.

\*\*\*p<.0001.

**Table 3. Proportions scoring above cut-off by outcome and timepoint.**

Outcome	Pr1 Time-point	Pr2 Time-point	Pr1	Pr2	diff <sub>Pr1-Pr2</sub>	Lower CI <sub>.95</sub>	Upper CI <sub>.95</sub>	n
PHQ $\geq$ 15	T0	T1	0.52	0.27	0.25***	0.20	0.31	330
	T0	T3	0.56	0.17	0.39***	0.33	0.45	315
	T0	T6	0.51	0.16	0.35***	0.24	0.46	92
GAD $\geq$ 10	T0	T1	0.64	0.41	0.23***	0.17	0.29	333
	T0	T3	0.67	0.26	0.41***	0.35	0.47	305
	T0	T6	0.69	0.32	0.37***	0.23	0.52	72
PCL $\geq$ 14	T0	T1	0.79	0.59	0.20***	0.15	0.25	327
	T0	T3	0.84	0.45	0.39***	0.33	0.45	299
	T0	T6	0.87	0.58	0.29***	0.17	0.41	69

T0 = baseline; T1 = 1-month assessment; T3 = 3-month assessment; T6 = 6-month assessment.

\*\*\*p<.0001.



**Table 4. Proportions reporting MCIDs at endpoint compared to baseline.**

Outcome	Endpoint	Pr	Lower CI <sub>.95</sub>	Upper CI <sub>.95</sub>	n
PHQ	T1	0.53***	0.47	0.58	330
	T3	0.75***	0.70	0.79	315
	T6	0.70***	0.60	0.79	92
GAD	T1	0.50***	0.44	0.55	333
	T3	0.68***	0.62	0.73	305
	T6	0.65***	0.54	0.76	72
PCL	T1	0.32***	0.26	0.37	327
	T3	0.50***	0.44	0.56	299
	T6	0.48***	0.36	0.60	69

Note. MCID = 3 points for PHQ and GAD. MCID = 5 points for PCL.

T1 = 1-month assessment; T3 = 3-month assessment; T6 = 6-month assessment.

\*\*\*p<.0001.

**Figure 1. Patient Flow Diagram**

